Aim and focus of the Liver.net Biobank
The SFB 841 aims at development of new strategies and starting points for diagnosis and therapy of liver diseases. The gained results might allow development of new diagnostic methods, more precise prognosis for chronic liver diseases or the identification and validation of new therapeutic target structures. This goal requires a tight connection between basic research and clinical expertise, the investigation of patient samples and the linkage of clinical data with the insights gained by the research projects.
The biobank aims at supporting this network. It provides a platform for standardized sample collection, sample storage and data linkage. The biobank therefore facilitates and promotes mainly four aspects: Sample storage & providing, linkage of the samples with clinical data, guarantee of the privacy issues and standardizing of procedures in order to improve reproducibility of the research results.
The statutes of the steering committee can be downloaded here in PDF format (in German language).
The biobank collects left over samples which can be rededicated for research. Sample types include tissue, blood samples and samples from other body fluids (such as urine, ascites, bile). Currently mainly EDTA blood, serum, urine, PaxGene, bile and liver tissue samples are stored in the biobank. Furthermore we are working on collecting PBMC-samples.
Basically left over samples are stored which can be rededicated for research.
The biobank operates under an existing ethics vote issued by the ethics committee of the Medical Chamber of Hamburg. The vote allows prospective collection of left over samples for investigation of liver diseases provided an existing patient consent. Single projects of the SFB 841 are not bound to apply for an independent ethics vote. Rather the use of the sample has to be reported to the ethics committee of the Medical Chamber of Hamburg accompanied by the patient consent and a summary of the patient information used.